Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2011 2
2012 1
2015 2
2016 1
2017 2
2019 1
2020 2
2021 4
2022 2
2023 4
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
Pittock SJ, Fujihara K, Palace J, Berthele A, Kim HJ, Oreja-Guevara C, Nakashima I, Levy M, Shang S, Yountz M, Miller L, Armstrong R, Wingerchuk DM; PREVENT Study Group. Pittock SJ, et al. Mult Scler. 2022 Mar;28(3):480-486. doi: 10.1177/13524585211038291. Epub 2021 Sep 9. Mult Scler. 2022. PMID: 34498507 Free PMC article. Clinical Trial.
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.
Neurodevelopmental Outcomes From the PREVeNT Trial.
O'Kelley SE, Capal JK, McPherson TO, Patrick KE, Pearson DA, Davis PE, Currans K, Byars AW, Porter BE, Sahin M, Taub KS, Rajaraman R, Randle S, McClintock WM, Koenig MK, Frost MD, Werner K, Nolan DA, Wong M, Krefting JL, Cutter GR, Krueger DA, Bebin EM; PREVeNT Study Group. O'Kelley SE, et al. Pediatr Neurol. 2025 Dec;173:88-97. doi: 10.1016/j.pediatrneurol.2025.09.006. Epub 2025 Sep 16. Pediatr Neurol. 2025. PMID: 41061327 Clinical Trial.
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial.
Bebin EM, Peters JM, Porter BE, McPherson TO, O'Kelley S, Sahin M, Taub KS, Rajaraman R, Randle SC, McClintock WM, Koenig MK, Frost MD, Northrup HA, Werner K, Nolan DA, Wong M, Krefting JL, Biasini F, Peri K, Cutter G, Krueger DA; PREVeNT Study Group. Bebin EM, et al. Ann Neurol. 2023 Aug 28:10.1002/ana.26778. doi: 10.1002/ana.26778. Online ahead of print. Ann Neurol. 2023. PMID: 37638552 Free PMC article.
Drug-Resistant Epilepsy in Tuberous Sclerosis Complex Is Associated With TSC2 Genotype: More Findings From the Preventing Epilepsy Using Vigatrin (PREVeNT) Trial.
Farach LS, Richard MA, Wulsin AC, Bebin EM, Krueger DA, Sahin M, Porter BE, McPherson TO, Peters JM, O'Kelley S, Taub KS, Rajaraman R, Randle SC, McClintock WM, Koenig MK, Frost MD, Werner K, Nolan DA, Wong M, Cutter G, Northrup H, Au KS; PREVeNT Study Group. Farach LS, et al. Pediatr Neurol. 2024 Oct;159:62-71. doi: 10.1016/j.pediatrneurol.2024.06.012. Epub 2024 Jul 4. Pediatr Neurol. 2024. PMID: 39142021
Using machine learning for personalized prediction of longitudinal coronavirus disease 2019 vaccine responses in transplant recipients.
Azarfar G, Sun Y, Pasini E, Sidhu A, Brudno M, Humar A, Kumar D, Bhat M, Ferreira VH; PREVenT Study Group; PREVenT-COVID Group investigators; PREVenT-COVID Group coordinators. Azarfar G, et al. Am J Transplant. 2025 May;25(5):1107-1116. doi: 10.1016/j.ajt.2024.11.033. Epub 2024 Dec 4. Am J Transplant. 2025. PMID: 39643006 Free article.
Prophylactic Mesh Placement During Formation of an End-colostomy: Long-term Randomized Controlled Trial on Effectiveness and Safety.
Brandsma HT, Hansson BM, Aufenacker TJ, de Jong N, V Engelenburg KC, Mahabier C, Donders R, Steenvoorde P, de Vries Reilingh TS, Leendert van Westreenen H, Wiezer MJ, de Wilt JHW, Rovers M, Rosman C; Dutch Prevent Study Group. Brandsma HT, et al. Ann Surg. 2023 Sep 1;278(3):e440-e446. doi: 10.1097/SLA.0000000000005801. Epub 2023 Jan 24. Ann Surg. 2023. PMID: 36727747 Clinical Trial.
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
Palace J, Wingerchuk DM, Fujihara K, Berthele A, Oreja-Guevara C, Kim HJ, Nakashima I, Levy M, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Yountz M, Miller L, Armstrong R, Pittock S; PREVENT Study Group. Palace J, et al. Mult Scler Relat Disord. 2021 Jan;47:102641. doi: 10.1016/j.msard.2020.102641. Epub 2020 Nov 26. Mult Scler Relat Disord. 2021. PMID: 33310418 Free article. Clinical Trial.
Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
Kim HJ, Nakashima I, Viswanathan S, Wang KC, Shang S, Miller L, Yountz M, Wingerchuk DM, Pittock SJ, Levy M, Berthele A, Totolyan N, Palace J, Barnett MH, Fujihara K; PREVENT Study Group. Kim HJ, et al. Mult Scler Relat Disord. 2021 May;50:102849. doi: 10.1016/j.msard.2021.102849. Epub 2021 Feb 20. Mult Scler Relat Disord. 2021. PMID: 33676197 Free article. Clinical Trial.
21 results